Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) CFO Alexis Desieno sold 8,854 shares of Cardlytics stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total transaction of $32,494.18. Following the completion of the sale, the chief financial officer now owns 121,976 shares in the company, valued at $447,651.92. This trade represents a 6.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Alexis Desieno also recently made the following trade(s):
- On Friday, November 15th, Alexis Desieno sold 25,118 shares of Cardlytics stock. The shares were sold at an average price of $3.43, for a total transaction of $86,154.74.
Cardlytics Trading Down 2.6 %
Shares of NASDAQ:CDLX opened at $3.35 on Thursday. Cardlytics, Inc. has a 52-week low of $2.89 and a 52-week high of $20.52. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. The company has a market capitalization of $170.25 million, a P/E ratio of -0.55 and a beta of 1.53. The company has a 50-day simple moving average of $3.89 and a 200 day simple moving average of $4.77.
Analysts Set New Price Targets
A number of equities analysts have recently commented on CDLX shares. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Finally, Evercore ISI began coverage on Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target for the company. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.92.
View Our Latest Stock Analysis on Cardlytics
Hedge Funds Weigh In On Cardlytics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Atom Investors LP bought a new position in shares of Cardlytics in the third quarter valued at about $33,000. XTX Topco Ltd acquired a new stake in Cardlytics during the second quarter worth approximately $107,000. SG Americas Securities LLC bought a new stake in shares of Cardlytics during the third quarter worth approximately $45,000. Intech Investment Management LLC acquired a new position in shares of Cardlytics in the third quarter valued at approximately $47,000. Finally, Quest Partners LLC increased its stake in shares of Cardlytics by 160.4% during the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock worth $147,000 after purchasing an additional 11,061 shares during the period. 68.10% of the stock is owned by institutional investors.
About Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Featured Articles
- Five stocks we like better than Cardlytics
- Best Stocks Under $5.00
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- What is the MACD Indicator and How to Use it in Your Trading
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Upcoming IPO Stock Lockup Period, Explained
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.